Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China

Table 2 Adverse events with nab-paclitaxel plus gemcitabine and gemcitabine alone

	AG			GEM			P value	P value
	Grade 1/2 (%)	Grade 3/4 (%)	Grade 5 (%)	Grade 1/2 (%)	Grade 3/4 (%)	Grade 5 (%)		Grade ≥ 3
White blood cell count decreased	8 (26.7)	9 (30.0)	0	7 (23.3)	6 (20.0)	0	0.549	0.371
Neutropenia	5 (16.7)	13 (43.3)	0	4 (13.3)	9 (30.0)	0	0.435	0.284
Anemia	10 (33.3)	3 (10.0)	0	6 (20.0)	3 (10.0)	0	0.489	1.000
Thrombocytopenia	5 (16.7)	3 (10.0)	0	2 (6.7)	2 (6.7)	0	0.394	0.639
Fatigue	9 (30.0)	4 (13.3)	0	6 (20.0)	2 (6.7)	0	0.382	0.385
Vomiting	10 (33.3)	3 (10.0)	1 (3.3)	8 (26.7)	0	1 (3.3)	0.168	0.148
Diarrhea	8 (26.7)	1 (3.3)	0	6 (20.0)	0	0	0.392	1.000
Fever	8 (26.7)	2 (6.7)	0	5 (16.7)	1 (3.3)	0	0.496	0.550
Febrile neutropenia	2 (6.7)	4 (13.3)	1 (3.3)	3 (10.0)	1 (3.3)	0	0.296	0.073
Infection	2 (6.7)	1 (3.3)	1 (3.3)	1 (3.3)	1 (3.3)	0	0.615	0.550
Sensory neuropathy	14 (46.7)	15 (50.0)	1 (3.3)	7 (23.3)	0	0	< 0.001	< 0.001

AG: Nab-paclitaxel plus gemcitabine; GEM: Gemcitabine.